Expressing the sense of the House of Representatives that over 25 years of real-world evidence and hundreds of peer-reviewed studies proving that mifepristone is safe and effective should be respected, and law and policy governing access to lifesaving, time-sensitive medication abortion care in the United States should be equitable, transparent, and based on the best available peer-reviewed evidence-based science.

H.Res. 1285, introduced in the 119th Congress on May 14, 2026, expresses the House of Representatives' sense that the safety and efficacy of mifepristone, supported by over 25 years of real-world evidence and numerous peer-reviewed studies, should be acknowledged. The bill advocates for equitable, transparent, and science-based access to medication abortion care in the United States, emphasizing the importance of respecting the established evidence surrounding mifepristone.